
Erasca to Present at the Guggenheim Securities SMID-Cap Biotech Conference
Erasca, Inc. Announces Participation in Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being…